Compare VPG & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VPG | ATAI |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.6M | 1.4B |
| IPO Year | N/A | 2021 |
| Metric | VPG | ATAI |
|---|---|---|
| Price | $41.02 | $4.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $44.00 | $14.33 |
| AVG Volume (30 Days) | 148.4K | ★ 3.3M |
| Earning Date | 02-11-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $299,283,000.00 | $3,018,000.00 |
| Revenue This Year | $0.44 | $943.18 |
| Revenue Next Year | $5.01 | N/A |
| P/E Ratio | $65.83 | ★ N/A |
| Revenue Growth | N/A | ★ 811.78 |
| 52 Week Low | $18.57 | $1.15 |
| 52 Week High | $40.60 | $6.75 |
| Indicator | VPG | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 68.09 | 44.77 |
| Support Level | $37.67 | $3.64 |
| Resistance Level | $39.81 | $4.19 |
| Average True Range (ATR) | 1.40 | 0.25 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 92.69 | 31.02 |
Vishay Precision Group Inc manufactures and markets sensors, and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.